[go: up one dir, main page]

MA49837A - Compositions pharmaceutiques - Google Patents

Compositions pharmaceutiques

Info

Publication number
MA49837A
MA49837A MA049837A MA49837A MA49837A MA 49837 A MA49837 A MA 49837A MA 049837 A MA049837 A MA 049837A MA 49837 A MA49837 A MA 49837A MA 49837 A MA49837 A MA 49837A
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
MA049837A
Other languages
English (en)
Inventor
Gary Cook
Sally Louise Marsh
Stephen John Pethen
Michael Bryan Roe
Christopher Martyn Yea
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of MA49837A publication Critical patent/MA49837A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA049837A 2017-08-11 2018-08-13 Compositions pharmaceutiques MA49837A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762544346P 2017-08-11 2017-08-11
GBGB1713660.7A GB201713660D0 (en) 2017-08-25 2017-08-25 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
MA49837A true MA49837A (fr) 2020-06-17

Family

ID=60037096

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049837A MA49837A (fr) 2017-08-11 2018-08-13 Compositions pharmaceutiques

Country Status (13)

Country Link
US (1) US20200261383A1 (fr)
EP (1) EP3664780A1 (fr)
JP (1) JP2020530475A (fr)
KR (1) KR20200038987A (fr)
CN (1) CN111032018A (fr)
AU (1) AU2018315034A1 (fr)
BR (1) BR112020002325A2 (fr)
CA (1) CA3071772A1 (fr)
GB (1) GB201713660D0 (fr)
MA (1) MA49837A (fr)
SG (1) SG11202001179YA (fr)
TW (1) TW201919600A (fr)
WO (1) WO2019030540A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
EP4010333A1 (fr) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Inhibiteurs de la kallicréine plasmatique
GB2591730A (en) * 2019-12-09 2021-08-11 Kalvista Pharmaceuticals Ltd New polymorphs
GB201918994D0 (en) 2019-12-20 2020-02-05 Kalvista Pharmaceuticals Ltd Treatments of diabetic macular edema and impaired visual acuity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070258976A1 (en) * 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
GB2494851A (en) * 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
JP6250646B2 (ja) * 2012-05-25 2017-12-20 ノバルティス アーゲー 生物学的治療薬およびグアニジンまたはグアニジン誘導体を含む水性医薬組成物、並びに該組成物を含む注射剤
GB2510407A (en) * 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration

Also Published As

Publication number Publication date
CN111032018A (zh) 2020-04-17
US20200261383A1 (en) 2020-08-20
TW201919600A (zh) 2019-06-01
GB201713660D0 (en) 2017-10-11
WO2019030540A1 (fr) 2019-02-14
AU2018315034A1 (en) 2020-02-27
SG11202001179YA (en) 2020-03-30
KR20200038987A (ko) 2020-04-14
BR112020002325A2 (pt) 2020-09-01
CA3071772A1 (fr) 2019-02-14
EP3664780A1 (fr) 2020-06-17
JP2020530475A (ja) 2020-10-22

Similar Documents

Publication Publication Date Title
DK3529248T3 (da) Farmaceutiske sammensætninger
DK3256138T3 (da) Farmaceutiske sammensætninger omfattende meloxicam
MA50541A (fr) Formulations pharmaceutiques
EP3641771A4 (fr) Compositions pharmaceutiques
EP3280421A4 (fr) Compositions pharmaceutiques pour thérapie combinée
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
LT3655038T (lt) Farmacinė kompozicija
MA42303A (fr) Formulations pharmaceutiques
DK3634377T3 (da) Farmaceutisk formulering
EP3603642A4 (fr) Préparation pharmaceutique
EP3454899C0 (fr) Composition pharmaceutique
EP3541385A4 (fr) Formulations pharmaceutiques
MA45187A (fr) Combinaisons pharmaceutiques
EP3573614C0 (fr) Compositions pharmaceutiques pour thérapie combinée
MA54716A (fr) Réduction de la viscosité de formulations pharmaceutiques
EP3310439A4 (fr) Compositions pharmaceutiques pour des applications anesthésiologiques
PL3703518T3 (pl) Formulacja ulegająca aerozolowaniu
MA49837A (fr) Compositions pharmaceutiques
DK3583943T3 (da) Farmaceutisk sammensætning
EP3389633A4 (fr) Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
EP3646866A4 (fr) Préparation pharmaceutique
DK3280447T3 (da) Farmaceutiske formuleringer
EP3302483A4 (fr) Compositions pharmaceutiques et utilisation de celles-ci
EP3727485C0 (fr) Composition pharmaceutique